FRTX vs. UNCY, AIM, PMCB, EVAX, IKT, APTO, COEP, ONVO, CLDI, and CHRO
Should you be buying Fresh Tracks Therapeutics stock or one of its competitors? The main competitors of Fresh Tracks Therapeutics include Unicycive Therapeutics (UNCY), AIM ImmunoTech (AIM), PharmaCyte Biotech (PMCB), Evaxion Biotech A/S (EVAX), Inhibikase Therapeutics (IKT), Aptose Biosciences (APTO), Coeptis Therapeutics (COEP), Organovo (ONVO), Calidi Biotherapeutics (CLDI), and Chromocell Therapeutics (CHRO). These companies are all part of the "medical" sector.
Unicycive Therapeutics (NASDAQ:UNCY) and Fresh Tracks Therapeutics (NASDAQ:FRTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership.
Unicycive Therapeutics received 24 more outperform votes than Fresh Tracks Therapeutics when rated by MarketBeat users. Likewise, 70.59% of users gave Unicycive Therapeutics an outperform vote while only 0.00% of users gave Fresh Tracks Therapeutics an outperform vote.
In the previous week, Unicycive Therapeutics had 2 more articles in the media than Fresh Tracks Therapeutics. MarketBeat recorded 2 mentions for Unicycive Therapeutics and 0 mentions for Fresh Tracks Therapeutics. Fresh Tracks Therapeutics' average media sentiment score of 0.56 beat Unicycive Therapeutics' score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the media.
Fresh Tracks Therapeutics has higher revenue and earnings than Unicycive Therapeutics. Fresh Tracks Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Unicycive Therapeutics currently has a consensus target price of $5.63, indicating a potential upside of 1,130.85%. Given Fresh Tracks Therapeutics' higher possible upside, research analysts clearly believe Unicycive Therapeutics is more favorable than Fresh Tracks Therapeutics.
40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 25.0% of Fresh Tracks Therapeutics shares are owned by institutional investors. 24.1% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Fresh Tracks Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Fresh Tracks Therapeutics' return on equity of 0.00% beat Unicycive Therapeutics' return on equity.
Unicycive Therapeutics has a beta of 2.39, suggesting that its stock price is 139% more volatile than the S&P 500. Comparatively, Fresh Tracks Therapeutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500.
Summary
Unicycive Therapeutics beats Fresh Tracks Therapeutics on 14 of the 17 factors compared between the two stocks.
Get Fresh Tracks Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fresh Tracks Therapeutics Competitors List
Related Companies and Tools
Free FRTX Stock Alerts